Scarica l'app Stockscreener
4.21
4.73%
0.19
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$4.02
Aprire:
$4.04
Volume 24 ore:
1.07M
Relative Volume:
16.05
Capitalizzazione di mercato:
$175.32M
Reddito:
-
Utile/perdita netta:
$-19.90M
Rapporto P/E:
-6.7903
EPS:
-0.62
Flusso di cassa netto:
$-19.80M
1 W Prestazione:
+2.18%
1M Prestazione:
-1.86%
6M Prestazione:
+38.49%
1 anno Prestazione:
+69.08%
Intervallo 1D:
$4.03
$4.33
Intervallo di 1 settimana:
$3.92
$4.33
Portata 52W:
$2.14
$4.95
Diamedica Therapeutics Inc Stock (DMAC) Company Profile
Nome
Diamedica Therapeutics Inc
Settore
Industria
Telefono
(763) 496-5454
Indirizzo
301 CARLSON PARKWAY, MINNEAPOLIS, MN
Confronta DMAC con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
| DMAC | 4.21 | 175.32M | 0 | -19.90M | -19.80M | -0.62 |
| VRTX | 449.47 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 748.65 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 589.07 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 247.16 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 107.06 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Diamedica Therapeutics Inc Stock (DMAC) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2021-04-09 | Iniziato | Oppenheimer | Outperform |
| 2021-02-17 | Iniziato | ROTH Capital | Buy |
| 2020-10-30 | Iniziato | Guggenheim | Buy |
| 2020-07-08 | Iniziato | Maxim Group | Buy |
| 2019-04-30 | Iniziato | Dougherty & Company | Buy |
| 2019-03-05 | Iniziato | Lake Street | Buy |
Mostra tutto
Diamedica Therapeutics Inc Borsa (DMAC) Ultime notizie
We're Not Very Worried About DiaMedica Therapeutics' (NASDAQ:DMAC) Cash Burn Rate - Yahoo Finance
HC Wainwright Reaffirms Buy Rating for DiaMedica Therapeutics (NASDAQ:DMAC) - MarketBeat
DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Q3 2024 Earnings Call Transcript - Insider Monkey
DiaMedica Therapeutics Reports Q3 2024 Financial Results - TipRanks
DMACDiaMedica Therapeutics Inc. Latest Stock News & Market Updates - StockTitan
DiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2024 Financial Results - BioSpace
DiaMedica Launches Phase 2 Trial for Novel Preeclampsia Treatment DM199 | DMAC Stock News - StockTitan
DiaMedica (DMAC) to Present at Craig-Hallum Conference: Spotlight on DM199 Stroke Treatment | DMAC Stock News - StockTitan
DiaMedica Therapeutics to Participate in Upcoming Craig-Hallum 15th Annual Alpha Select Conference - Business Wire
DiaMedica Therapeutics (DMAC) Set to Announce Quarterly Earnings on Wednesday - MarketBeat
DiaMedica Therapeutics to Provide a Business Update and Report Third Quarter 2024 Financial Results November 14, 2024 - BioSpace
DiaMedica (DMAC) Sets Q3 2024 Earnings Call, Updates on DM199 Pipeline Progress | DMAC Stock News - StockTitan
Blue Trust Inc. Makes New Investment in DiaMedica Therapeutics Inc. (NASDAQ:DMAC) - Defense World
DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Sees Large Growth in Short Interest - MarketBeat
Best Momentum Stocks to Buy for October 14th - Yahoo Canada Finance
Head to Head Contrast: DiaMedica Therapeutics (NASDAQ:DMAC) versus Provectus Biopharmaceuticals (OTCMKTS:PVCT) - Defense World
DiaMedica shares maintain Buy rating from H.C. Wainwright - Investing.com
DiaMedica shares maintain Buy rating from H.C. Wainwright By Investing.com - Investing.com South Africa
DiaMedica gets SAHPRA approval for Phase II preeclampsia treatment trial - Yahoo Finance
DiaMedica advances preeclampsia treatment with trial approval By Investing.com - Investing.com South Africa
DiaMedica advances preeclampsia treatment with trial approval - Investing.com India
DiaMedica Therapeutics Announces Regulatory Approval to Begin Phase 2 Trial of DM199 in the Treatment of Preeclampsia - Business Wire
Research Analysts Offer Predictions for DiaMedica Therapeutics Inc.'s Q3 2024 Earnings (NASDAQ:DMAC) - MarketBeat
H.C. Wainwright initiates DiaMedica shares with Buy rating on stroke treatment By Investing.com - Investing.com South Africa
H.C. Wainwright initiates DiaMedica shares with Buy rating on stroke treatment - Investing.com India
DiaMedica Therapeutics (NASDAQ:DMAC) Coverage Initiated by Analysts at HC Wainwright - MarketBeat
This Fastenal Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
DiaMedica: Readying For REDUX Readout - RTTNews
Magnolia Capital Advisors LLC Buys New Stake in DiaMedica Therapeutics Inc. (NASDAQ:DMAC) - Defense World
Point72 DIFC Ltd Acquires Shares of 2,848 Mettler-Toledo International Inc. (NYSE:MTD) - Defense World
Commonwealth Equity Services LLC Invests $303,000 in Diebold Nixdorf, Incorporated (NYSE:DBD) - Defense World
US FDA Closes Out Problem Applications One Federal Register Notice At A Time - Pink Sheet
Ameritas Investment Partners Inc. Has $1.82 Million Stake in Dolby Laboratories, Inc. (NYSE:DLB) - Defense World
Domino’s Pizza, Inc. (NYSE:DPZ) Position Lowered by Epoch Investment Partners Inc. - Defense World
Victory Capital Management Inc. Sells 10,924 Shares of Dolby Laboratories, Inc. (NYSE:DLB) - Defense World
Dolby Laboratories, Inc. (NYSE:DLB) Shares Sold by Federated Hermes Inc. - Defense World
Deftones’ Album Rises To A New Peak–Nearly 20 Years After Its Release - Forbes
Deutsche Telekom downgraded to Neutral from Outperform at Oddo BHF - TipRanks
Insiders See US$9.05m Investment In DiaMedica Therapeutics Jump Last Week - Simply Wall St
DiaMedica Therapeutics (NASDAQ:DMAC) Shares Up 2.7% - Defense World
DiaMedica Therapeutics (NASDAQ:DMAC) Trading Up 2.7% - MarketBeat
DMAC stock touches 52-week high at $4.11 amid bullish trend - Investing.com
DiaMedica Therapeutics Upcoming Conference Participation - Business Wire
Is Atossa Genetics (ATOS) Outperforming Other Medical Stocks This Year? - Yahoo Finance
DMAC stock touches 52-week high at $3.85 amid robust gains - Investing.com
DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Shares Purchased by Vanguard Group Inc. - Defense World
Vanguard Group Inc. Acquires 211,351 Shares of DiaMedica Therapeutics Inc. (NASDAQ:DMAC) - MarketBeat
Oppenheimer Reiterates “Outperform” Rating for DiaMedica Therapeutics (NASDAQ:DMAC) - Defense World
DiaMedica Therapeutics' (DMAC) Outperform Rating Reaffirmed at Oppenheimer - MarketBeat
DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Short Interest Update - MarketBeat
DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Short Interest Down 17.0% in July - Defense World
Diamedica Therapeutics Inc Azioni (DMAC) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Diamedica Therapeutics Inc Azioni (DMAC) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| STAHLBERG JAN | 10% Owner |
Jun 28 '24 |
Buy |
2.50 |
1,200,000 |
3,000,000 |
5,221,608 |
1.80%
0.42%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):